|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CU |
First Approval Date01 Jun 2008 |
A Phase II/III Trial to Assess the Safety, Immunogenicity and Preliminary Efficacy of Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Administered to Patients With Non-Small-Cell Lung Cancer (NSCLC) After Receiving Conventional First Line Chemotherapy
The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).
100 Clinical Results associated with Bioven Sdn. Bhd.
0 Patents (Medical) associated with Bioven Sdn. Bhd.
100 Deals associated with Bioven Sdn. Bhd.
100 Translational Medicine associated with Bioven Sdn. Bhd.